- Home
- SCLX
as 04-23-2025 4:00pm EST
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 51.3M | IPO Year: | N/A |
| Target Price: | $396.67 | AVG Volume (30 days): | 103.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -21.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.80 - $80.50 | Next Earning Date: | 05-12-2025 |
| Revenue: | $56,590,000 | Revenue Growth: | 21.07% |
| Revenue Growth (this year): | 115.3% | Revenue Growth (next year): | 73.33% |
Latest Scilex Holding Company News
SCLX Breaking Stock News: Dive into SCLX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
GlobeNewswire
7 days ago
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
GlobeNewswire
9 days ago
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada
TipRanks
12 days ago
Scilex downgraded to Hold from Buy at D. Boral Capital
GlobeNewswire
13 days ago
Scilex Holding Company Announces 1-for-35 Reverse Stock Split
GlobeNewswire
a month ago
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
GlobeNewswire
a month ago
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
Simply Wall St.
2 months ago
Breakeven Is Near for Scilex Holding Company (NASDAQ:SCLX)
Compare SCLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCLX Scilex Holding Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.